Workflow
百花医药(600721) - 2022 Q1 - 季度财报
BHCBHC(SH:600721)2022-04-28 16:00

Financial Performance - The company's operating revenue for Q1 2022 was CNY 58,796,482.88, representing a year-on-year increase of 24.40%[5] - The net profit attributable to shareholders of the listed company was CNY 1,372,156.64, up 28.00% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 945,756.27, an increase of 122.20% year-on-year[5] - Basic earnings per share were CNY 0.0037, an increase of 27.59% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥58,796,482.88, a 24.3% increase from ¥47,264,446.74 in Q1 2021[17] - Net profit for Q1 2022 was ¥1,378,890.58, representing a 27.3% increase compared to ¥1,083,387.72 in Q1 2021[17] - Total profit for Q1 2022 was ¥2,005,268.37, up from ¥1,763,077.94 in Q1 2021, reflecting a growth of 13.7%[17] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -12,682,485.50, reflecting a decrease of 6.89% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥12,682,485.50 in Q1 2022, slightly improved from a net outflow of ¥13,620,328.17 in Q1 2021[19] - The company's cash and cash equivalents decreased to RMB 49,289,567.66 from RMB 86,884,849.85, representing a decline of about 43.3%[13] - The company reported cash and cash equivalents of ¥49,289,567.66 at the end of Q1 2022, down from ¥41,785,041.34 at the end of Q1 2021[20] Expenses and Investments - The company's research and development expenses increased by 282.09% compared to the same period last year, indicating a significant investment in R&D[7] - Research and development expenses rose significantly to ¥4,354,071.54 in Q1 2022, compared to ¥1,139,542.38 in Q1 2021, marking an increase of 282.5%[17] - Sales expenses rose by 130.88% year-on-year, primarily due to the expansion of the sales team for business growth[7] - The company experienced a decrease in investment income, reporting a loss of ¥684,735.13 in Q1 2022 compared to a gain of ¥43,802.21 in Q1 2021[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 980,924,866.39, a slight decrease of 0.14% from the end of the previous year[5] - As of March 31, 2022, the total current assets amounted to RMB 474,176,742.25, a slight increase from RMB 468,093,854.92 at the end of 2021, reflecting a growth of approximately 1.2%[13] - Total liabilities as of March 31, 2022, were RMB 293,293,913.94, a decrease from RMB 296,060,953.02 at the end of 2021, reflecting a reduction of approximately 0.9%[15] - The total equity of the company was RMB 687,630,952.45, slightly up from RMB 686,252,061.87, showing an increase of about 0.2%[15] - Non-current assets totaled RMB 506,748,124.14, down from RMB 514,219,159.97, reflecting a decrease of approximately 1.5%[14] - The company’s total assets were RMB 980,924,866.39, slightly lower than RMB 982,313,014.89 at the end of 2021, indicating a decrease of about 0.1%[14] - The company’s contract liabilities increased to RMB 90,640,179.23 from RMB 85,727,394.43, representing a growth of approximately 5.0%[15] Government Support - The company received government subsidies amounting to CNY 388,403.94, which are closely related to its normal business operations[7]